Wittkopp T A
J Clin Psychiatry. 1978 Feb;39(2):154-7.
In an open study of 4-weeks duration, both an oral liquid concentrate formulation of loxapine hydrochloride (LOXITANE C) and capsules of loxapine succinate (LOXITANE) were administered to 11 acutely disturbed schizophrenic patients. Optimal dosage levels achieved with the concentrate proved satisfactory with the capsules. Efficacy evaluation with the Brief Psychiatric Rating Scale (BPRS), Systematic Nurses' Observation of Psychopathology (SNOOP), and Clinical Global Impressions (CGI) indicated rapid improvement with concentrate administration and continued improvement with capsule administration. All but two side effects were extrapyramidal or sedative, all but one were mild or moderate in severity, and the frequency was similar with the two formulations. Cardiovascular and clinical laboratory findings remained essentially unchanged with both formulations.
在一项为期4周的开放性研究中，对11名急性精神错乱的精神分裂症患者给予了盐酸洛沙平口服浓缩液制剂（氯氮平C）和琥珀酸洛沙平胶囊（氯氮平）。结果表明，浓缩液达到的最佳剂量水平用胶囊也令人满意。采用简明精神病评定量表（BPRS）、护士精神病理学系统观察量表（SNOOP）和临床总体印象量表（CGI）进行的疗效评估表明，给予浓缩液后病情迅速改善，给予胶囊后持续改善。除两例外，所有副作用均为锥体外系或镇静作用，除一例外，严重程度均为轻度或中度，两种制剂的发生率相似。两种制剂的心血管和临床实验室检查结果基本保持不变。
